ANI Pharmaceuticals (ANIP) Given a $74.00 Price Target by Cantor Fitzgerald Analysts

Cantor Fitzgerald set a $74.00 price target on ANI Pharmaceuticals (NASDAQ:ANIP) in a research report sent to investors on Tuesday. The firm currently has a buy rating on the specialty pharmaceutical company’s stock.

ANIP has been the subject of several other reports. Zacks Investment Research lowered shares of ANI Pharmaceuticals from a buy rating to a hold rating in a research report on Tuesday, July 10th. BidaskClub lowered shares of ANI Pharmaceuticals from a sell rating to a strong sell rating in a research report on Wednesday, September 19th. ValuEngine lowered shares of ANI Pharmaceuticals from a buy rating to a hold rating in a research report on Saturday, July 28th. Finally, Canaccord Genuity set a $75.00 price target on shares of ANI Pharmaceuticals and gave the stock a buy rating in a research report on Thursday, August 16th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The stock has a consensus rating of Hold and a consensus target price of $71.00.

NASDAQ ANIP traded down $1.38 during trading hours on Tuesday, hitting $52.66. 78,559 shares of the company’s stock traded hands, compared to its average volume of 73,741. The company has a current ratio of 3.34, a quick ratio of 2.89 and a debt-to-equity ratio of 1.04. The firm has a market capitalization of $653.68 million, a price-to-earnings ratio of 14.59 and a beta of 2.64. ANI Pharmaceuticals has a 52 week low of $48.40 and a 52 week high of $74.70.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its earnings results on Tuesday, November 6th. The specialty pharmaceutical company reported $1.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.17 by $0.12. The company had revenue of $50.70 million during the quarter, compared to analyst estimates of $50.97 million. ANI Pharmaceuticals had a net margin of 0.23% and a return on equity of 28.39%. The firm’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same period in the previous year, the business posted $1.11 earnings per share. Sell-side analysts predict that ANI Pharmaceuticals will post 4.49 EPS for the current year.

Institutional investors and hedge funds have recently bought and sold shares of the business. Teachers Retirement System of The State of Kentucky boosted its position in shares of ANI Pharmaceuticals by 99.5% in the third quarter. Teachers Retirement System of The State of Kentucky now owns 2,005 shares of the specialty pharmaceutical company’s stock worth $113,000 after purchasing an additional 1,000 shares during the period. Bessemer Group Inc. bought a new position in shares of ANI Pharmaceuticals in the third quarter worth approximately $138,000. Piedmont Investment Advisors LLC bought a new position in shares of ANI Pharmaceuticals in the second quarter worth approximately $140,000. Truvestments Capital LLC bought a new position in shares of ANI Pharmaceuticals in the third quarter worth approximately $152,000. Finally, Stifel Financial Corp bought a new position in shares of ANI Pharmaceuticals in the first quarter worth approximately $215,000. Institutional investors and hedge funds own 61.10% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. It focuses on producing controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. The company offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and hydrocortisone enema and cortenema to treat ulcerative colitis.

Featured Story: Price to Earnings Ratio (PE)

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit